Therapeutics for COVID-19
SS Toussi, JL Hammond, BS Gerstenberger… - Nature …, 2023 - nature.com
Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …
(COVID-19) illness were available within a year of the pandemic being declared but there …
Accelerating antiviral drug discovery: lessons from COVID-19
During the coronavirus disease 2019 (COVID-19) pandemic, a wave of rapid and
collaborative drug discovery efforts took place in academia and industry, culminating in …
collaborative drug discovery efforts took place in academia and industry, culminating in …
Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2
DC Schultz, RM Johnson, K Ayyanathan, J Miller… - Nature, 2022 - nature.com
The SARS-CoV-2 virus has infected more than 261 million people and has led to more than
5 million deaths in the past year and a half (https://www. who. org/). Individuals with SARS …
5 million deaths in the past year and a half (https://www. who. org/). Individuals with SARS …
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …
[HTML][HTML] Therapeutics for COVID-19 and post COVID-19 complications: An update
Since its inception in late December 2020 in China, novel coronavirus has affected the
global socio-economic aspect. Currently, the world is seeking safe and effective treatment …
global socio-economic aspect. Currently, the world is seeking safe and effective treatment …
Drug combinations as a first line of defense against coronaviruses and other emerging viruses
The world was unprepared for coronavirus disease 2019 (COVID-19) and remains ill-
equipped for future pandemics. While unprecedented strides have been made developing …
equipped for future pandemics. While unprecedented strides have been made developing …
The inherent flexibility of receptor binding domains in SARS-CoV-2 spike protein
Spike (S) protein is the primary antigenic target for neutralization and vaccine development
for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It decorates the …
for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It decorates the …
Broad‐spectrum prodrugs with anti‐SARS‐CoV‐2 activities: Strategies, benefits, and challenges
Z Wang, L Yang - Journal of medical virology, 2022 - Wiley Online Library
In this era, broad‐spectrum prodrugs with anti‐severe acute respiratory syndrome
coronavirus 2 (SARS‐CoV‐2) activities are gaining considerable attention owing to their …
coronavirus 2 (SARS‐CoV‐2) activities are gaining considerable attention owing to their …
Forodesine and Riboprine Exhibit Strong Anti-SARS-CoV-2 Repurposing Potential: In Silico and In Vitro Studies
Lately, nucleos (t) ide antivirals topped the scene as top options for the treatment of
coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome …
coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome …
Repurposing and computational design of PARP inhibitors as SARS-CoV-2 inhibitors
Abstract Coronavirus disease 2019 (COVID-19) is a recent pandemic that caused serious
global emergency. To identify new and effective therapeutics, we employed a drug …
global emergency. To identify new and effective therapeutics, we employed a drug …